Analysis Of The Weekly Performance Of Humanigen Inc. (HGEN)


Humanigen Inc. (NASDAQ:HGEN) finished Thursday with a subtraction of -$0.01 to close at $0.09, a downside of -0.63 percent. An average of 3,026,040 shares of common stock have been traded in the last five days. There was a fall of -$0.0065 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 1,913,735 shares traded, while the 50-day average volume stands at 2,032,270.

HGEN stock has decreased by -33.52% in the last month. The company shares reached their 1-month lowest point of $0.0924 on 12/29/22. With the stock rallying to its 52-week high on 03/21/22, shares of the company touched a low of $0.09 and a high of $4.13 in 52 weeks. It has reached a new high 4 times so far this year and lost -97.46% or -$3.6254 in price. In spite of this, the price is down -97.71% from the 52-week high.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Valuation Metrics

Humanigen Inc. (HGEN) stock’s beta is -0.84. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.13.

Financial Health

The quick ratio of Humanigen Inc. for the three months ended September 29 was 0.30, and the current ratio was 0.30, indicating that the company is not able to meet its debt obligations. Its gross profit as reported stood at $236.37 million compared to revenue of $3.6 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Humanigen Inc.’s return on assets was -199.60%.

Earnings Surprise

In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$23.69 million in the quarter, while revenues were shrunk -181.72%. The analyst consensus anticipated Humanigen Inc.’s latest quarter earnings to come in at -$0.18 per share, but it turned out to be -$0.23, a -27.80% surprise. For the quarter, EBITDA amounted to -$22.72 million. At the end of the quarter ending September 29, Humanigen Inc.’s stock balance sheet showed total liabilities of 78.37 million. Shareholders own equity worth $119.08 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Humanigen Inc. (HGEN) price momentum. RSI 9-day as of the close on 29 December was 26.15%, suggesting the stock is oversold, with historical volatility in this time frame at 96.68%.

As of today, HGEN’s price is $0.0997 -6.43% or -$0.0065 from its 5-day moving average. HGEN is currently trading -33.38% lower than its 20-day SMA and -75.31% lower than its 100-day SMA. However, the stock’s current price level is -41.64% below the SMA50 and -96.38% below the SMA200.

The stochastic %K and %D were 4.21% and 11.17%, respectively, and the average true range (ATR) was 0.0114. With the 14-day stochastic at 4.62% and the average true range at 0.0117, the RSI (14) stands at 29.38%. The stock has reached -0.0103 on the 9-day MACD Oscillator while the 14-day reading was at -0.0168.

Analyst Ratings

ROTH Capital downgraded Humanigen Inc. (NASDAQ: HGEN) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a Buy.

What is HGEN’s price target for the next 12 months?

Analysts predict a range of price targets between $0.50 and $9.00, with a median target of $4.75. Taking a look at these predictions, the average price target given by analysts for Humanigen Inc. (HGEN) stock is $4.75.


Please enter your comment!
Please enter your name here